Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?
Crossref DOI link: https://doi.org/10.1007/s00277-016-2899-0
Published Online: 2016-12-23
Published Print: 2017-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Paubelle, Etienne
Ducastelle-Leprêtre, Sophie
Labussière-Wallet, Hélène
Nicolini, Franck Emmanuel
Barraco, Fiorenza
Plesa, Adriana
Salles, Gilles
Wattel, Eric
Thomas, Xavier
License valid from 2016-12-23